Cetuximab and Envafolimab Plus mFOLFOXIRI as First-line Treatment for RAS/BRAF Wild-type, MSS, Unresectable Left-side Metastatic Colorectal Cancer

NCT05959356 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

198

Enrollment

OTHER

Sponsor class

Conditions

Metastatic Colorectal Cancer

Interventions

DRUG: Cetuximab + Envafolimab + mFOLFOXIRI
DRUG: Cetuximab + mFOLFOX6

Sponsor

Sun Yat-sen University